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Abstract
Clusterin (CLU) is a chaperone‐like protein with multiple functions. sCLU is frequently
upregulated in prostate tumor cells after chemo‐ or radiotherapy and after surgical or
pharmacological castration. Moreover, CLU has been documented to modulate the
cellular homolog of murine thymoma virus akt8 oncogene (AKT) activity. Here, we
investigated how CLU overexpression influences phosphatidylinositol 3′‐kinase (PI3K)/
AKT signaling in human normal and cancer epithelial prostate cells. Human prostate cells
stably transfected with CLU were broadly profiled by reverse phase protein array (RPPA),
with particular emphasis on the PI3K/AKT pathway. The effect of CLU overexpression on
normal and cancer cell motility was also tested. Our results clearly indicate that CLU
overexpression enhances phosphorylation of AKT restricted to isoform 2. Mechanistically,
this can be explained by the finding that the phosphatase PH domain leucine‐rich repeat‐
containing protein phosphatase 1 (PHLPP1), known to dephosphorylate AKT2 at S474, is
markedly downregulated by CLU, whereas miR‐190, a negative regulator of PHLPP1, is
upregulated. Moreover, we found that phosphatase and tensin homolog (PTEN) was
heavily phosphorylated at the inhibitory site S380, contributing to the hyperactivation of
AKT signaling. By keeping AKT2 phosphorylation high, CLU dramatically enhances the
migratory behavior of prostate epithelial cell lines with different migratory and invasive
phenotypes, namely prostate normal epithelial 1A (PNT1A) and prostatic carcinoma 3
(PC3) cells. Altogether, our results unravel for the first time a circuit by which CLU can
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switch a low migration phenotype toward a high migration phenotype, through miR‐190‐
dependent downmodulation of PHLPP1 expression and, in turn, stabilization of AKT2
phosphorylation.
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1 | INTRODUCTION
The many functions of the ubiquitously expressed protein clusterin
(CLU) are mirrored by the multiplicity of its names (Apolipoprotein J,
testosterone‐repressed prostate message 2, and sulfate glyprotein‐2
among others). Under physiological conditions, the predominant
translation product of the human gene is a 80 kDa heterodimeric,
disulfide‐linked, and highly glycosylated secretory protein, sCLU,
mainly characterized by the chaperoning function as well as the
cytoprotective activity (Bonacini et al., 2015; Choi‐Miura, Takahashi,
Nakano, Tobe, & Tomita, 1992; Kim & Choi, 2011; Leskov, Klokov, Li,
Kinsella, & Boothman, 2003; Prochnow et al., 2013; Pucci, Mazzarelli,
Nucci, Ricci, & Spagnoli, 2009; Rizzi & Bettuzzi, 2010; Rosenberg &
Silkensen, 1995; Shannan et al., 2006). This cytoprotective chaper-
oning role is particularly evident upon stress where sCLU increases
the solubility of denatured proteins and mediates the uptake and
degradation of a broad spectrum of hydrophobic denatured
aggregated molecules (Poon, Treweek, Wilson, Easterbrook‐Smith,
& Carver, 2002; Viard et al., 1999). Moreover, sCLU associates to,
and stabilizes, the Ku70‐Bax complex in the cytoplasm (Djeu & Wei,
2009; Pucci et al., 2017) and is therefore believed to play an
important role in survival and resistance to chemotherapeutic drugs
(Koltai, 2014; Zhou et al., 2015). However, the elucidation of CLU's
broad range of functions has been partly hampered by the finding
that under cell stress or damage, a number of forms can be produced
from the evolutionary conserved CLU gene either through alter-
native splicing/noncanonical translation/initiation start sites or
eluding the glycosylation steps necessary for secretion (Bonacini
et al., 2015; Prochnow et al., 2013). These intracellular forms display
different intracellular localizations and, in some case, almost opposite
biological functions (Al Nakouzi et al., 2016; July et al., 2002; Rizzi &
Bettuzzi, 2009; Rohne, Prochnow, & Koch‐Brandt, 2016).
Interestingly, CLU has been shown to affect the phosphatidylinositol
3′‐kinase (PI3K)‐AKT pathway (Ammar & Closset, 2008; Jo, Jia,
Subramanian, Hattori, & Luo, 2008; Ma & Bai, 2012). This pathway is
the central hub of oncogenic signaling and has been linked to
tumorigenesis in a wide variety of tumor types (Manning & Toker,
2017; Ruzzene, Bertacchini, Toker, & Marmiroli, 2017). In normal cells,
stimulation of growth factor receptors activates acute production of
phosphatidylinositol‐3,4,5‐triphosphate (PIP3) by PI3K, thus triggering
dual AKT phosphorylation: at T308, by PDK1, and at S473, by mTORC2.
Fully active AKT, in turn, enhances cell proliferation and survival
(Fruman & Rommel, 2014). Eventually, dephosphorylation of PIP3 by the
lipid phosphatase PTEN and/or dephosphorylation of AKT S473 by
PHLPP1/2 protein phosphatases turn off AKT signaling (Gao, Furnari, &
Newton, 2005; Newton & Trotman, 2014). Activation of PI3K/AKT
signaling has been widely implicated in prostate cancer progression
(Bertrand, McCubrey, Angus, Nutter, & Sigounas, 2014; Manning &
Toker, 2017; McCubrey et al., 2015; Newton & Trotman, 2014).
Molecular alterations such as mutations, chromosomal aberrations, and
altered expression of the key pathway components have been reported
in 42% of primary and 100% of metastatic prostate cancers (Chen et al.,
2011; Newton & Trotman, 2014; Taylor et al., 2010). The majority of the
above abnormalities include decreased expression of PTEN and/or of
PHLPPs, therefore leading to constitutively active AKT signaling.
Interestingly, PHLPP1 mRNA is downregulated in high‐grade prostate
cancer, suggesting that PHLPP1 loss contributes to other genetic
aberrations to promote prostate cancer progression. Moreover, a study
performed with AKT isoform‐silencing showed that contrary to other
models such as breast cancer cells, AKT1 and AKT2 cooperate to
enhance the migration and invasion of PC3 cells through upregulation of
β1‐integrin (Virtakoivu, Pellinen, Rantala, Perälä, & Ivaska, 2012). On the
other hand, AKT1 and AKT2 were described to play nonredundant
functions in PC3 cell migration, possibly through distinct subcellular
localization. Furthermore, it has been suggested that AKT isoform‐
specific contribution might differ during prostate cancer progression,
from androgen‐sensitive to hormone‐resistant stage (Cariaga‐Martinez
et al., 2013). Therefore, mechanistically the peculiar roles of AKT
isoforms in prostate cancer cell migration and invasion, if any, have not
been conclusively settled. Here, we unravel a yet‐undescribed regulatory
system driven by sCLU, which modulates PHLPP1 level, leading to
constitutive activation of AKT2 and enhanced migration and invasion of
both normal and cancer prostate cells.
2 | MATERIALS AND METHODS
2.1 | Cell Cultures and Inhibitors
Human prostate carcinoma PC3 cell line was obtained from deutsche
sammlung von mikroorganismen und zellkulturen (DSMZ) (Braunsch-
weig, Germany). Normal prostate epithelial PNT1A cells stably
transfected with empty vector pIRES‐hyg1 or pIRES‐CLU were a kind
gift from the laboratory of Dr. Saverio Bettuzzi (University of Parma,
Italy; Scaltriti et al., 2004), and will hereafter be referred to as CLU and
MOCK cells, respectively. PNT1A and PC3 cells were grown in RPMI
1640, Hamʼs F12 and Dulbecco's modified minimum essential medium
(DMEM) supplemented with 1% L‐glutamine, 10% heat‐inactivated
fetal bovine serum (Euroclone, Milano, Italy), and antibiotics (Sigma‐
Aldrich, Darmstadt, Germany), at 37°C in a humidified atmosphere with
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5% CO2. Where indicated, the AKT2‐selective inhibitor XII (Merck
Millipore, Milano, Italy) was used at 0.5 µM.
The MTT assay was performed in 96‐well plates. Ten thousand
cells/well were seeded, and the cells were cultured for 24 and 48 hr.
MTT (Sigma‐Aldrich, Darmstadt, Germany) was dissolved in PBS at
5mg/ml, and 20 μl of MTT solution was added to each well followed
by 3 hr of incubation at 37°C, 5% CO2. Then, plates were read out by
an ELISA reader (LifeTech, MA) at 590 nm.
Cell proliferation was monitored by propidium iodide (PI) staining.
After harvesting, the cells were washed twice with PBS and resuspended
in 100 μl binding buffer (10mM HEPES/NaOH, of pH 7.4, 140mM NaCl,
2.5mM CaCl2 and 50 μg/ml PI). The samples were incubated for 10min
in the dark at 4°C and then analyzed by flow cytometry.
2.2 | Transfections
For transient CLU overexpression, cells were transfected with
polyethyleneimine (PEI) in a 3:1 ratio of PEI (µg): total DNA (µg).
Control cells were transfected with empty vector. CLU silencing was
performed with specific siRNA, and the cells were transfected for 72 hr
with siRNA transfection reagent as described in the supplierʼs
instruction manual. For negative control, the cells were transfected
with 100 nM scramble siRNA (all from Santa Cruz Biotechnology, Santa
Cruz, CA). Where required, AKT1 and AKT2 were silenced with a set of
AKT1 or AKT2 target shRNAs, kindly provided by the laboratory of Alex
Toker (Beth Israel Deaconess Center, Boston). shAKT1 and shAKT2
were transduced in cells for 72 hr by lentiviral supernatant obtained in
packaging hosts HEK293 cells as described (Chin & Toker, 2010).
Infected cells were selected with 5 µg/ml of Puromycin for 48 hr.
2.3 | Immunoblotting and Immunofluorescence
Cell lysis was performed on ice for 20min in a lysis buffer suitable for
both reverse phase protein array (RPPA) and immunoblotting, as
described previously (Maraldi et al., 2011). Briefly, for immunoblot-
ting, lysates were sonicated three times for 10 seconds on ice, then
centrifuged at 10,000 g for 15min at 4°C, and denatured at 100°C
for 5 min in SDS‐loading buffer, run on a 7% SDS‐PAGE, then
transferred to an Immobilon‐P PVDF membrane (Merck Millipore,
Milano, Italy), and incubated overnight at 4°C with primary
antibodies (Cenni et al., 2008). A list of antibodies is provided in
Table 1S. For immunofluorescence, anti‐PIP3 and anti‐PIP2 anti-
bodies (Echelon Biosciences, Salt Lake City, UT) were used at 1:50
dilution. The cells were analyzed using a Nikon Eclipse TE2000
inverted microscope, and fluorescent images were captured with a
Hamamatsu camera (Hamamatsu City, Japan), as described pre-
viously (Cenni et al., 2014; Maraldi et al., 1993).
2.4 | Reverse phase protein array
For RPPA, protein lysates were diluted to a final concentration of
0.5mg/ml, and then 30 μl were loaded on a 383‐well plate and
subjected to immunostaining with a panel of 82 commercially available,
validated antibodies directed against specific phosphorylated or cleaved
proteins, all from Cell Signaling Technology (Table 1S), as described
(Bertacchini et al., 2014; Maraldi et al., 2011; Serafin et al., 2017).
2.5 | RNA purification and real‐time quantitative
polymerase chain reaction
Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Valencia,
CA) and reverse‐transcribed with the High capacity cDNA Reverse
Transcription kit (Applied Biosystem, Foster City, CA) according to the
manufacturerʼs instructions. Quantification of miR‐190 was performed
with a miRCURY LNA Universal RT miR cDNA synthesis kit, SYBR
Green master mix, Universal RT, and LNA PCR primer. Primer
sequences are the following: PHLPP1, forward: 5′‐TGCTCACT
CCAACTGCATCGAG‐3′ reverse: 5′‐GGTTTCCAGTCAGGTCTAGCT
C‐3′. miR‐190, forward: 5′‐TGATATGTTTGATATATTAGG‐3′ reverse:
5′‐GAACATGTCTGCGTATCTC‐3′. Glyceraldehyde 3‐phosphate dehy-
drogenase, forward: 5′‐CGAGATCCCTCCAAAATCAA‐3′ reverse:
5′‐TTCACACCCATGACGAACAT‐3′. The relative gene expression
quantification was based on the comparative threshold cycle method
−▵▵2 Ct . Raw data were normalized to the included housekeeping gene.
2.6 | Cell Migration and invasion assay
Migration experiments were performed both by the transwell
migration assay and by the XCELLigence RTCA System (CaRli
biotech, Roma, Italy). For transwell migration experiments, 105 cells
were resuspended in 200 μl of RPMI + BSA 3% and added to the
upper chamber of a two‐chamber device separated by the porous
membrane (polycarbonate membrane inserts 8‐μM pore size;
Corning, NY). The lower chambers were filled with 600 μl of NIH‐
3T3 cells medium or with conditioned medium from CLU cells or with
recombinant CLU. The cells were incubated at 37°C for 48 hr to
allow cell migration through the membrane. Migratory cells were
stained with the hematoxylin (HEMA) 3 STAIN kit (Thermo Scientific
Fisher, Milano, Italy) and counted under a Nikon Eclipse TE2000
inverted microscope. Migration and invasion experiments with the
xCELLigence RTCA System (Roche Applied Science, Mannheim,
Germany) were performed following the manufacturer instructions,
as described previously (Brugnoli et al., 2013; Grassilli et al., 2014).
Briefly, 4 × 104 cells/well were seeded onto the top chambers of
CIM‐16 plates while the bottom chambers were filled with NIH‐3T3
cells medium or with the CLU‐conditioned medium. The signal
detection was programmed every 15min for a total of 48 hr.
Impedance values were expressed as relative arbitrary units.
2.7 | Statistical analysis
Data were expressed as the mean ± standard deviation (SD). Differences
were tested by Studentʼs t test. The values p <0.05 were considered
statistically significant, and were indicated by an asterisk *. The
statistical analysis was done using the PRISM GraphPad statistical
software. For RPPA, to detect differences between total protein
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F IGURE 1 Clusterin enhances the PI3K signaling pathway at multiple levels. (a) Heatmap from the RPPA analysis of PNT1A cells stably
transfected with empty vector (MOCK) or with clusterin (CLU). The colors in each cell indicate the signal intensities of single antibodies (RED, high
intensity, WHITE low intensity). (b) Bar chart of key components of the PI3K/AKT cascade from (a). The X‐axis reports all endpoints tested
(phosphorylated epitopes where indicated); The Y‐axis reports the fold‐change ratio of signal intensity in CLU versus MOCK samples. The arbitrary
unit of MOCK was set as 1, while the cutoff magnitude to qualify changes in specific proteins phosphorylation as significant was set as 1.2‐fold. (c)
Lysates from the above analysis were resolved by the Western blot analysis and probed with the indicated antibodies. Note that the anti‐AKT S473
antibody detects both phosphorylated AKT1 S473 and AKT2 S474. The lower panel shows a comparison of AKT1 and two isoforms, both total and
phosphorylated, in MOCK and CLU lysates by means of isoform‐specific antibodies. The lower‐right panel shows AKT2 and AKT1 silencing in CLU
cells by isoform‐specific shRNA. CLU cells transfected with scramble shRNA were run as a control. (d) Bar panel with quantitation of signal intensity
of each band, normalized to the loading control, as the ratio of optical densities (OD) phosphorylated versus total protein. (e) PIP3, PIP2, and the CLU
immunofluorescence analysis. Representative immunofluorescence photomicrographs of MOCK and CLU cells, showing PIP3, PIP2, and CLU content.
Dilution: anti‐PIP3 and anti‐PIP2 (Echelon Laboratories), 1:50 dilution; anti‐CLU, 1:100 (Millipore). Images were taken at a magnification of
×60. PI3K, phosphatidylinositol 3'‐kinase; PIP3, phosphatidylinositol‐3,4,5‐triphosphate; RPPA, reverse phase protein array [Color figure can be
viewed at wileyonlinelibrary.com]
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expression and phosphorylated protein expression, a paired t test was
performed. We set 1.2‐fold as the cutoff magnitude to qualify changes
in specific proteins as significant.
3 | RESULTS
3.1 | CLU modulates the PI3K pathway
MOCK and CLU cells were analyzed by RPPA to compare 82 native
and phosphorylated proteins operating in key signaling pathways.
Several endpoints were differentially expressed or phosphorylated
(Figure 1a and Supporting Information Figure 1S). In particular, CLU
cells showed a marked phosphorylation of proteins involved in the
PI3K/AKT/mTOR cascade, such as PDK1, PTEN, as well as AKT
itself and its direct substrates PRAS40 and Foxo (Figure 1b). This
observation was confirmed by the Western blot analysis (Figure 1c).
Although modulation of the AKT activity by CLU had been shown
previously (Ammar & Closset, 2008; Jo et al., 2008; Ma & Bai, 2012),
no molecular mechanism has been defined yet. We noticed that
AKT phosphorylated at S473 migrated as a doublet (Figure 1c).
Remarkably, while phosphorylation of the upper band was very
similar in the two cell subtypes, the lower band was heavily
phosphorylated in CLU cells but almost undetectable in MOCK cells.
The antibody used detects AKT1, AKT2, and AKT3 phosphorylation
at S473, S474, and S472, respectively, suggesting that the bands
could correspond to different isoforms. However, in these cells,
AKT3 is almost undetectable (not shown). By means of single
isoform‐silencing, the lower band proved to be AKT2, suggesting that
CLU exerts an isoform‐restricted control over AKT phosphorylation
(Figure 1c, lower‐right panel). This result, intriguing in itself, was even
more so because by the same analysis, we found that the expression
levels of the lipid phosphatase PTEN was almost doubled in CLU
compared with MOCK cells. As PTEN dephosphorylates PIP3
(Maehama & Dixon, 1998) and is therefore a well‐known negative
regulator of AKT (Milella et al., 2015; Myers et al., 1998; Song,
Salmena, & Pandolfi, 2012), this would suggest that a decrease,
rather than an increase, of the AKT activity should occur. Never-
theless, along with the increased PTEN expression, PTEN phosphor-
ylation at S380 was also altered, being dramatically higher in CLU
cells (Figure 1b, c). Thus, because S380 phosphorylation is known to
inhibit the PTEN phosphatase activity, while stabilizing the protein
against degradation (Barata, 2011; Vazquez, Ramaswamy, Nakamura,
& Sellers, 2000), we concluded that the high level of pS380‐PTEN in
CLU cells actually contributes to AKT hyperactivation. To confirm
this, we compared the content of PIP3 in MOCK and CLU cells by
immunofluorescence. In good agreement with the above‐mentioned
results, the staining intensity of PIP3 was significantly higher in CLU
cells with respect to the parental MOCK cells (Figure 1e). In contrast,
PIP2 levels were similar, suggesting that the increased PIP3 level
results more from PTEN downregulation than from PI3K activation
(Figure 1e). Although high PIP3 levels can explain the sustained
PDK1, S241, and AKT T308 phosphorylation, because the PI3K and
PTEN activity were not measured directly, we cannot rule out that
PIP3 derives from the PI3K activity rather than from PTEN
inactivation. To assess whether the T308 phosphatase PP2A may
also contribute to this mechanism, MOCK and CLU cells were
incubated for 60min with okadaic acid, a well‐known PP2A inhibitor,
and then the level of phospho‐T308 in the two cell types was
compared. In cells treated with okadaic acid and probed with anti‐
pT308, we observed a strong drop of the signal. However, it is also
clear that the degree of inhibition of PP2A is the same in MOCK and
CLU. Although not conclusive, this result suggests that the PP2A
activity is similar in both cell lines (Figure 2).
Altogether, these findings could account for the 2.5‐fold increase
in total AKT phosphorylation detected by RPPA in CLU cells but
could not explain the dramatic differential phosphorylation of AKT2‐
S474 in CLU cells. We, therefore, decided to monitor the amount of
the protein phosphatase specific to AKT2‐S474, namely PHLPP1. We
observed that PHLPP1 was markedly downregulated in CLU
compared to MOCK cells (Figure 2), a condition that, by itself, could
explain the AKT2 hyperactivity. PHLPP1 downmodulation was
clearly detectable not only in cells stably expressing CLU but also
in transiently transfected PNT1A cells, though to a lesser extent
(Figure 2). These results prompted us to investigate the interplay
between AKT2, PHLPP1, and CLU more deeply.
3.2 | CLU enhances miR‐190, which, in turn,
downmodulates PHLPP1
From the RPPA analysis, it was evident that both the phosphorylation of
GSK3 at its activatory residues and that of its main substrate β‐catenin, at
the GSK3 site S33/S37/T41, was more than doubled in CLU cells
(Supporting Information Figure 2S). Interestingly, Li, Liu, and Gao (2009)
demonstrated that PHLPP1 is a proteolytic target of the E3 ligase
β‐TrCP and undergoes proteasomal degradation upon sequential
phosphorylation by CK1 and GSK3. This suggested that CLU might
promote GSK3‐mediated PHLPP1 degradation. Moreover, we also
analyzed the effect of CLU overexpression on PHLPP1 expression.
Interestingly, we found that PHLPP1 mRNA was dramatically down-
regulated (>10‐fold) in PNT1A cells transfected with CLU, compared with
empty vector‐transfected controls (Figure 3a, left). Conversely, silencing
of endogenous CLU by specific siRNA triggered a 6‐ to 8‐fold increase in
PHLPP1 mRNA, clearly indicating that CLU indeed modulates its
F IGURE 2 The analysis of PHLPP1 levels in CLU overexpressing
cells. PHLPP1 was analyzed by the Western blot analysis in protein
extracts from MOCK and CLU cells, and from PNT1A cells
transfected with empty vector (ev) or with CLU for 24 hr, as
indicated, then probed with anti‐PHLPP1 from Bethyl Laboratories,
1:1,000. Lower panel, actin loading control. CLU, clusterin; PHLPP1,
PH domain leucine‐rich repeat‐containing protein phosphatase 1
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transcription. As PNT1A are normal prostatic epithelial cells, we
wondered whether CLU might display the same effects also in prostate
cancer cells, such as a highly tumorigenic PC3 cell line. We found that the
expression of PHLPP1 was unquestionably upregulated by CLU silencing
(>20‐fold) and downmodulated by overexpression, with a trend similar to
that observed in PNT1A cells, although to a greater extent (Figure 3a,
right). Recently, a number of miRs have been shown to control the
expression of PHLPPs (Grzechnik & Newton, 2016). In particular, miR‐
190 and miR‐214 have been shown by us and others to regulate PHLPPs
expression in prostate epithelial cells (Beezhold et al., 2011). Thus, we
asked whether CLU might tune PHLPP1 levels through such molecules.
The expression of both miR‐190 and miR‐214 was analyzed by real‐time
polymerase chain reaction. While the level of miR‐214 was not affected
(not shown), that of miR‐190 was significantly higher in CLU compared
with MOCK cells, and a similar increase was observed upon the forced
expression of CLU, particularly in PC3 cells (39‐fold increase; Figure 3b).
Thus, we conclude that CLU exerts a complex control of PHLPP1
phosphatase regulation mediated by an epigenetic mechanism involving
increased expression of miR‐190, which eventually leads to constitutive
phosphorylation of AKT2.
F IGURE 3 Modulation of PHLPP1
expression by CLU. (a) The RT‐PCR
analysis of PHLPP1 mRNA in PNT1A and
PC3 cells. CLU was either overexpressed
(CLU) or silenced with specific siRNA
(siRNA) by transfection for 72 hr. Control
cells were transfected with empty vector
(ev) or with a scrambled sequence
(scramble). **p < 0.05. (b) miR‐190 levels
were determined by RT‐PCR in MOCK,
CLU, and PNT1A cells from (a). (c) CLU
expression was probed in all the above
experimental points by the anticlusterin
Western blot analysis followed by anti‐
actin control of protein loading. Results
represent the means from three
independent experiments ± SD.
CLU, clusterin; PHLPP1, PH domain
leucine‐rich repeat‐containing protein
phosphatase 1; RT‐PCR, real‐time
polymerase chain reaction; SD, standard
deviation
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3.3 | CLU facilitates cell migration and invasion
through a PHLPP1‐AKT2 circuit
Overexpression of CLU has been reported to enhance the
metastatic behavior of human laryngeal squamous carcinoma
cells (Wang, Cao, Su, Liu, & Zhang, 2014), as well as renal
(Shi et al., 2013; Wang, Luo, Dong, Yu, & Zhao, 2014), breast (Niu
et al., 2012), and hepatocellular carcinoma (Wang et al., 2012).
Conversely, CLU was demonstrated to inhibit prostate cancer cell
migration by associating to α‐actinin and disassembling of the
actin cytoskeleton (Moretti et al., 2007; Rizzi & Bettuzzi, 2010).
Our results clearly indicated that CLU stable clone cells
F IGURE 4 CLU stimulates migration of normal prostate cells. (a) Bar graph representation of the cell migration analysis by the transwell
assay. Aliquots of the cells from the experimental points described in Figure 3a,b were seeded on transwells to analyze cell migration. Relative
migration was quantified by counting the number of violet and blue cells (HEMA staining) in three inserts. At least three different experiments
were performed. Results are average ± SD. Silencing of CLU in CLU cells by transfection with specific siRNA for 72 hr (which were not included
in the experimental set above) was confirmed by the Western blot analysis (figure [a] insert). Control CLU cells were transfected with a
scramble sequence. (b) To verify whether modulation of CLU expression affects cell proliferation or cell viability, aliquots of cells from the above
experimental points were analyzed for the cell cycle progression by PI staining followed by flow cytometry (left panels) and for cell proliferation
by the MTT assay (right panels). CLU, clusterin; MTT, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium; SD, standard deviation
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exhibited, over a 24‐hr time frame, a migration index more than
three‐fold higher than their MOCK counterpart. On the contrary,
silencing of CLU by specific siRNA strongly inhibited migration of
CLU cells (Figure 4a). Therefore, we analyzed the effects of CLU
transient overexpression on the migration of PNT1A cells, which
are not expected to display a high mobility phenotype. Remark-
ably, transient transfection of PNT1A cells for 48 hr was
sufficient to boost their migration almost to the levels of CLU
cells (Figure 4a). As the transwell assay used to evaluate
migration did not detect alterations of cell proliferation or cell
viability, the possibility that such effects might be evoked by CLU
during the 48‐hr time frame were ruled out by means of the
analysis of the cell cycle through PI staining and flow cytometry
as well as of the viability by the MTT assay (Figure 4b).
Next, we explored the effect of AKT silencing on migration of MOCK
versus CLU cells. We found that while AKT1 silencing affected migration
of neitherMOCK nor CLU cells, silencing of AKT2 prevented migration of
both cell types (Figure 5a). Treatment with the AKT2‐selective
pharmacological inhibitor AKT Inhibitor XII (Bulj et al., 2013; Zhao
et al., 2008) at a dose as low as 500nM, gave similar results (Figure 5c).
Altogether, these findings indicate that CLU likely controls prostate
epithelial cell migration predominantly through downregulation of
PHLPP1 and activation of AKT2.
Next, we investigated how CLU might affect the movement of
prostate cancer cells with an invasive phenotype. Thus, the
migration capability of PNT1A cells was compared with that of
PC3 cells, which display increased invasiveness, upon transfection
with either empty vector or with CLU. As expected, PC3 cells
displayed a higher basal migration index than PNT1A, which was
nevertheless dramatically increased by overexpression of CLU in
both cell types (Figure 6a). What's more important, we further
evaluated the effects of CLU expression in cells grown in a 3D
matrix. The results are clear and show that CLU overexpression
significantly stimulated cell invasion through Matrigel (Figure 6b).
These results are in complete agreement with the observation that
the expression of CLU increases, whereas its silencing decreases,
F IGURE 5 Effect of AKT isoform‐
silencing on CLU‐stimulated cell migration.
(a) The bar graph shows the relative
migration of MOCK and CLU cells after
AKT1 or AKT2 silencing with isoform‐
specific shRNAs. Migration was quantified
by HEMA staining in three inserts, as
described above. (b) Samples from each
experimental point were resolved by the
Western blot analysis and probed with
isoform‐specific antibodies to confirm
silencing. (c) Relative migration of MOCK
and CLU cells 48 hr upon addition to the
growth medium of the specific AKT2
inhibitor (XII) at 0.5 μM. Relative migration
was quantified as described above. (d)
AKT2 inhibition was confirmed by the
Western blot analysis with anti‐pAKT1/2.
At least three different migration
experiments were performed. Results are
average ± SD. CLU, clusterin; SD, standard
deviation
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PHLPP1 expression in both PNT1A and PC3 cells, while inversely
affecting MiR‐190. These results altogether conclude that CLU
exerts a migration and proinvasive effect on healthy epithelial
prostate cells through a miR‐190/PHLPP1/AKT 2 circuit.
4 | DISCUSSION
CLU is a small heat‐shocklike protein overexpressed in many solid
tumors with multiple functions but largely elusive molecular mechan-
isms. Work from independent laboratories has suggested that it can
modulate the PI3K/AKT pathway, although in a cell‐type and context‐
dependent manner. In particular, CLU has been shown to block the
PI3K activity through the association with insuline‐like growth factor
(IGF‐1) and inhibition of IGF‐1R during serum deprivation (Jo et al.,
2008), to mediate IGF‐1 induced activation of PI3K signaling in non‐
small‐cell lung cancer (Ma & Bai, 2012) or to activate AKT and promote
the survival of prostate cancer cells (Ammar & Closset, 2008). On the
other hand, AKT has been shown to upregulate sCLU which, in turn,
would mediate docetaxel resistance in prostate cancer cells (Zhong
et al., 2010). By a wide analysis of the phosphoproteome of normal
prostate PNT1A cells overexpressing CLU, the first part of our study
shows that CLU impinges on the PI3K/AKT cascade at multiple levels
and, by doing so, hyperactivates AKT. The enhanced phosphorylation of
AKT at T308 could be explained by our finding that in CLU cells, the
specific PIP3 phosphatase PTEN (Maehama & Dixon, 1998) is highly
phosphorylated at the inhibitory site T380 (Vazquez et al., 2000).
However, we unambiguously demonstrate for the first time that CLU
also evokes a dramatic differential phosphorylation of AKT2. Although
the parallel inactivation of PTEN can undeniably contribute to AKT2
activation, it cannot account for the observed isoform selectivity. Taking
advantage of the notion that the phosphatases, that dephosphorylate
AKT at S473, display an isoform‐specific activity (Gao et al., 2005;
Newton & Trotman, 2014), we disclose here that the AKT2‐specific
phosphatase, PHLPP1, is strongly downregulated in CLU cells. PHLPP1
has been reported to undergo proteasome‐dependent degradation after
phosphorylation by GSK3 and CK1 in colon cancer cells (Li et al., 2009).
While on the one hand, our results suggest that CLU overexpression
might in part promote such mechanism also in normal prostate cells, on
the other hand, we have clearly demonstrated that CLU mainly acts by
preventing mRNA translation of PHLPP1. Importantly, because it has
been recently demonstrated that PHLPP expression can be modulated
F IGURE 6 Modulation of normal and
cancer cell motility by CLU. PNT1A and
PC3 cells from the same pool analyzed in
Figure 3 (transfected with empty vector or
with CLU) were run with the xCELLigence
System to evaluate the modulation of
migration (a) and invasion (b) by CLU. The
relative migration index is indicated in the
Y‐axis. Migration and invasion experiments
were repeated two times. Results are
average ± SD. CLU, clusterin; SD, standard
deviation
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through specific miRs (Beezhold et al., 2011), and in particular in
prostate cancer cells by the upregulation of miR‐190 and miR‐214, we
investigated whether CLU alters the expression of these molecules.
Although we did not observe any change in miR‐214 level, we were able
to show that the intracellular content of miR‐190 in cells either
transfected with or exposed to CLU is indeed affected to a very large
extent (up to a 39‐fold increase in PC3 cells). An opposite result was
obtained by CLU silencing. In light of the effects of CLU on PHLPP1
expression and the resulting peculiar phosphorylation pattern of AKT
isoforms, we assessed whether CLU might affect cell motility. A
pioneering work by Scaltriti et al. (2004) suggested that CLU counter-
acts cell migration and invasion. Conversely, more recent works from
different laboratories indicate that it enhances cell migration in several
cell models (Jin et al., 2012; Niu et al., 2012). Although there is some
evidence that in macrophages, CLU promotes chemotactic migration
through upregulation of matrix metalloproteinase‐9 and NF‐kB activa-
tion downstream of AKT and Erk1/2 (Shim et al., 2011; Shim, Kang,
Choi, Park, & Min, 2012), hitherto its molecular mechanisms in prostate
cells have remained elusive. We show that overexpression of CLU
triggers migration both in normal and in cancer prostate cells, and is
sufficient to increase the migration index of normal PNT1A cells to the
same level of the highly metastatic PC3 prostate cancer cells.
Conversely, CLU silencing prevents migration in both cell types. In
particular, on the basis of the effects of specific silencing of either AKT1
or AKT2, we further demonstrate that CLU drives cell migration
through AKT2. Inhibition of the AKT2 activity by the isoform‐specific
allosteric inhibitor AKTi XII supported this conclusion. A CLU‐induced
decrease in PHLPP1 expression is in complete agreement with this
function of AKT2. Moreover, we demonstrate that CLU overexpression
is sufficient to boost PC3 cell invasion through a 3D Matrigel, whereas
CLU silencing completely abrogates it.
Thus, all together, our results clearly demonstrate for the first
time that the CLU promigration activity is controlled by the PHLPP/
AKT axis, as CLU can switch the low migration and invasion
phenotype of normal prostate cells toward the high migration
phenotype typical of cancer PC3 cells through the modulation of
the expression of PHLPP1 and, in turn, the activity of AKT2.
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